Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCPZYT)

Drug Name

CV-9201 Drug Info

Synonyms

CV-9201-1; CV-9201-2; CV-9201-3; CV-9201-4; CV-9201-5; RNA-based vaccine (NY-ESO-1, MAGE-C1/CT7, MAGE-C2/CT10, NSCLC), CureVac

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 1/2	[1]

Cross-matching ID

TTD Drug ID: DMCPZYT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Apoptosis inhibitor survivin (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS 23722	DMQZI7K	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
SurVaxM	DMAIGTE	Glioblastoma of brain	2A00.00	Phase 2	[5]
EZN-3042	DMXFY18	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
------------------------------------------------------------------------------------

Drug(s) Targeting Oncotrophoblast glycoprotein 5T4 (TPBG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TroVax	DMHDNK0	Prostate cancer	2C82.0	Phase 3	[7]
Naptumomab estafenatox	DM901ZW	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[8]
GEN1044	DMQ9317	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
PF-06263507	DM5KBDY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
IM1240	DMTV0DK	Aggressive cancer	2A00-2F9Z	Preclinical	[11]
Anatumomab mafenatox	DMMLDG8	Breast cancer	2C60-2C65	Terminated	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting Cancer/testis antigen 1 (NY-ESO-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CDX-1401	DMCGNJ6	Ovarian cancer	2C73	Phase 2	[13]
Anti-NY-ESO-1 CAR-T cells	DM26VCZ	Esophageal cancer	2B70	Phase 1/2	[14]
NY-ESO-1 vaccine	DM0EKUQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
GSK-2241658A	DM5VS7B	Melanoma	2C30	Phase 1	[16]
GSK3901961	DMN4I7P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
GSK3845097	DM1UQ4Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apoptosis inhibitor survivin (BIRC5)	TTTPU1G	BIRC5_HUMAN	Not Available	[2]
Cancer/testis antigen 1 (NY-ESO-1)	TTE5ITK	CTG1B_HUMAN	Not Available	[2]
Cancer/testis antigen MAGE-C1/CT7 (MAGEC1)	TT9M6NA	MAGC1_HUMAN	Not Available	[3]
Melanoma-associated antigen C2 (MAGEC2)	TTKGUEB	MAGC2_HUMAN	Not Available	[2]
Oncotrophoblast glycoprotein 5T4 (TPBG)	TT70MLA	TPBG_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00923312) Trial of an RNActive-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC). U.S. National Institutes of Health.
2	National Cancer Institute Drug Dictionary (drug id 648549).
3	National Cancer Institute Drug Dictionary (drug id 648549).
4	Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.Eur J Cancer.2012 Mar;48(5):763-71.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	SPC3042: a proapoptotic survivin inhibitor.Mol Cancer Ther.2008 Sep;7(9):2736-45.
7	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47.
8	Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
9	Clinical pipeline report, company report or official report of AbbVie.
10	National Cancer Institute Drug Dictionary (drug id 751006).
11	Clinical pipeline report, company report or official report of Purple
12	A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.
13	National Cancer Institute Drug Dictionary (drug id 651880).
14	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
15	Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822.
16	ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
17	Clinical pipeline report, company report or official report of GlaxoSmithKline.
18	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.